Glufosfamide

葡膦酰胺

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameGlufosfamide
Drug Alias Name葡磷酰胺glufosfamideglufosfamidumglufosfamidaglc-IPM +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA synthesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsSmall Cell Lung CarcinomaOvarian NeoplasmsPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdBaxter International IncQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhaoke Pharmaceutical (Hefei) Co LtdPharmaceutics International IncEleison Pharmaceuticals Llc
Inactive CompaniesThreshold Pharmaceuticals
Active IndicationsPancreatic Neoplasms
Inactive IndicationsSmall Cell Lung CarcinomaOvarian NeoplasmsSarcoma +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia